Prime Medicine (PRME) Operating Leases (2021 - 2026)

Prime Medicine (PRME) has 6 years of Operating Leases data on file, last reported at $114.5 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Leases rose 45.69% year-over-year to $114.5 million; the trailing twelve-month figure through Mar 2026 stood at $114.5 million (up 45.69% YoY), and the FY2025 full-year result was $108.3 million, up 191.26% from the prior year.
• Operating Leases for Q1 2026 stood at $114.5 million, up from $108.3 million in the prior quarter.
• Across five years, Operating Leases topped out at $114.5 million in Q1 2026 and bottomed at $4.4 million in Q4 2023.
• The 5-year median for Operating Leases is $33.6 million (2024), against an average of $50.8 million.
• The widest annual swing landed in 2023, when Operating Leases slumped 74.45%; it then surged 753.34% in 2024.
• A 5-year view of Operating Leases shows it stood at $17.1 million in 2022, then plunged by 74.45% to $4.4 million in 2023, then soared by 753.34% to $37.2 million in 2024, then soared by 191.26% to $108.3 million in 2025, then gained by 5.75% to $114.5 million in 2026.
• The last three Operating Leases figures came in at $114.5 million (Q1 2026), $108.3 million (Q4 2025), and $110.4 million (Q3 2025), per Business Quant data.

Peer Comparison